Register now for IPA's upcoming Journal Club!
NEW JOURNAL CLUB - REGISTER NOW
Lecanemab in Early Alzheimer’s Disease
[ September 26th, 2023 at 7:00 AM CDT ]
Dr. Chertkow will present on the article Lecanemab in Early Alzheimer’s Disease (C.H. van Dyck, et al). You can review this open access article here.
By the end of the session participants will be able to:
Is there hope in the treatment of Alzheimer’s Disease? Lecanemab has been approved by the FDA in the United States of America, and other countries may follow. In this iteration of the IPA Journal Club, we will look carefully at the 2023 New England Journal of Medicine study and have a robust discussion.
Dr. Chertkow is a cognitive neurologist at the Baycrest Health Sciences Centre. He is a Senior Scientist and Chair in Cognitive Neurology and Innovation at Baycrest’s Rotman Research Institute. He is a Professor in the Dept. of Medicine (Neurology) at University of Toronto. At Baycrest he is also director of the new Bank Family Clinical Trials Research Unit and the Kimel Family Centre for Brain Health. His major areas of research interest include early diagnosis of Alzheimer’s disease, and therapy of dementia using neuromodulation approaches such as transcranial direct current stimulation. Dr. Chertkow is Scientific Director for the Canadian Consortium on Neurodegeneration in Aging (CCNA), a national organization established by the Canadian government via CIHR and partners.
JOURNAL CLUB ORGANIZER:
Please don't hesitate to contact the IPA Secretariat with any questions or concerns prior to the event.